[2] [5] At present, there are no GLP-1 patches licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) or approved by the National Institute for Health and Care Excellence (NICE) for routine use in the United Kingdom (as verified through MHRA and Electronic Medicines Compendium searches, January 2024)
Patients must also consider the financial implications, as off-label use may not be NHS-funded, potentially incurring substantial private costs
116 Study details | Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and diet in inflammatory bowel disease (IBD) patients | ClinicalTrials.gov
The authors reported that retatrutide treatment for 48 weeks resulted in substantial reductions in body weight compared with placebo [1]
They seem to contain ingredients like green tea extract or cinammon that have very limited data when ingested , and Ive never even seen them tested as a sticker or a patch
One concern of using these medications, which inherently reduce energy intake through various satiety mechanisms, is that this delicate balance could be upset
